#1 Clinical Trials Search in Europe

Bortezomib

Bortezomib, also known by its brand name Velcade, is a promising drug being studied in various clinical trials for the treatment of different types of cancer. This article explores how bortezomib is being used in clinical trials to potentially improve outcomes for patients with conditions like multiple myeloma, lymphoma, and other cancers. We’ll look at how it works, what types of cancers it’s being tested for, and what researchers hope to learn from these studies.

Table of Contents

Introduction

Bortezomib, also known by the brand name Velcade[1], is an important medication used in the treatment of certain blood cancers, particularly multiple myeloma. This article will provide an overview of Bortezomib, including what it is, how it works, and its use in various clinical trials for treating blood cancers.

What is Bortezomib?

Bortezomib is a type of drug known as a proteasome inhibitor[2]. It was initially developed for use in multiple myeloma, a cancer that affects plasma cells in the bone marrow. Bortezomib represents a novel class of anti-cancer drugs that work differently from traditional chemotherapy medications[3].

Conditions Treated with Bortezomib

Bortezomib is primarily used to treat:

  • Multiple Myeloma: This is the main condition for which Bortezomib was developed and is most commonly used[1][3][4].
  • Waldenström Macroglobulinemia: This is a rare type of blood cancer that is also being treated with Bortezomib in clinical trials[2].
  • Light Chain Deposition Disease (LCDD) and other forms of Monoclonal Immunoglobulin Deposition Disease (MIDD): These are rare conditions associated with multiple myeloma that are also being studied for treatment with Bortezomib[5].
  • AL Amyloidosis: Another rare disease related to the abnormal production of certain proteins in the bone marrow[5].

How Bortezomib Works

Bortezomib works by inhibiting proteasomes, which are large protein complexes in cells that help break down old or damaged proteins. Cancer cells, particularly those in multiple myeloma, rely heavily on proteasomes to manage their rapid protein production. By inhibiting proteasomes, Bortezomib causes an accumulation of proteins in cancer cells, leading to their death[2].

How Bortezomib is Administered

Bortezomib is typically administered in the following ways:

  • Intravenous (IV) injection
  • Subcutaneous (SC) injection (under the skin)[4]

The dosage and frequency of administration can vary depending on the specific treatment protocol, but common schedules include:

  • 1.3 mg/m² on days 1, 4, 8, and 11 of a 21-day cycle[2]
  • Weekly administration in some protocols[4]

Combination Therapies

Bortezomib is often used in combination with other drugs to enhance its effectiveness. Some common combinations include:

  • Bortezomib, Thalidomide, and Dexamethasone (VTD)[1]
  • Bortezomib, Cyclophosphamide, and Dexamethasone (VCD)[1]
  • Bortezomib and Dexamethasone (BD)[5]
  • Melphalan, Prednisone, Thalidomide, and Bortezomib (MPTV)[3]

Ongoing Clinical Trials

Several clinical trials are ongoing to further investigate the effectiveness of Bortezomib in various conditions and treatment regimens. These include:

  • Comparing VTD vs VCD as induction treatment for newly diagnosed multiple myeloma[1]
  • Testing Bortezomib in advanced Waldenström Macroglobulinemia[2]
  • Evaluating Bortezomib as part of a comprehensive treatment approach for AL amyloidosis and MIDD[5]
  • Investigating prolonged maintenance therapy with Bortezomib in relapsed or refractory multiple myeloma[4]

Potential Side Effects

As with any medication, Bortezomib can cause side effects. Common side effects may include:

  • Fatigue
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Fever
  • Peripheral neuropathy (numbness or tingling in hands and feet)

It’s important to discuss potential side effects with your healthcare provider, as they can often be managed effectively[4].

Frequently Asked Questions

How effective is Bortezomib in treating multiple myeloma?

Bortezomib has shown significant effectiveness in treating multiple myeloma, both in newly diagnosed patients and those with relapsed or refractory disease. Clinical trials have demonstrated improved response rates and survival outcomes when Bortezomib is used alone or in combination with other drugs.

Can Bortezomib be used in elderly patients?

Yes, Bortezomib can be used in elderly patients. However, the dosage and treatment schedule may be adjusted based on the patient’s overall health and ability to tolerate the medication. It’s important for elderly patients to be closely monitored for side effects during treatment.

How long does Bortezomib treatment typically last?

The duration of Bortezomib treatment can vary depending on the specific condition being treated and the individual patient’s response. In some cases, it may be given for a fixed number of cycles (e.g., 4-6 cycles), while in others, it may be used as maintenance therapy for a longer period. The exact duration should be determined by the treating physician based on the patient’s individual circumstances.

Summary

Aspect Details
Drug Name Bortezomib (Velcade)
Drug Class Proteasome inhibitor
Main Conditions Treated Multiple Myeloma, Waldenström Macroglobulinemia, MIDD, AL Amyloidosis
Administration Intravenous or Subcutaneous injection
Common Combinations VTD, VCD, BD, MPTV
Key Benefits Improved response rates and survival outcomes in blood cancers
Ongoing Research Various clinical trials for different conditions and treatment regimens

Glossary

  • Multiple Myeloma – A type of blood cancer that affects plasma cells in the bone marrow
  • Waldenström Macroglobulinemia – A rare type of slow-growing blood cancer
  • Proteasome – A protein complex in cells that breaks down old or damaged proteins
  • AL Amyloidosis – A disease caused by the buildup of abnormal proteins in organs and tissues
  • Monoclonal Immunoglobulin Deposition Disease (MIDD) – A group of rare disorders characterized by the deposition of monoclonal immunoglobulin light and/or heavy chains

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT01971658
  • [2]: https://clinicaltrials.gov/study/NCT00777738
  • [3]: https://clinicaltrials.gov/study/NCT00358020
  • [4]: https://clinicaltrials.gov/study/NCT01913730
  • [5]: https://clinicaltrials.gov/study/NCT01383759
Aspect Details
Drug Name Bortezomib (Velcade, PS-341)
Drug Class Proteasome inhibitor
Main Cancers Studied Multiple myeloma, Non-Hodgkin’s lymphoma, Prostate cancer, Ovarian cancer
Administration Intravenous or subcutaneous injection
Common Dosing Schedule Days 1, 4, 8, and 11 of a 21 or 28-day cycle
Key Research Objectives Efficacy, safety, optimal dosing, combination therapies
Notable Side Effects Fatigue, nausea, diarrhea, decreased blood cell counts
Special Applications Treatment of graft-versus-host disease, overcoming drug resistance

FAQ

  • What is bortezomib and how does it work? Bortezomib is a type of drug called a proteasome inhibitor. It works by blocking certain proteins in cancer cells that are responsible for cell growth and survival. By interfering with these proteins, bortezomib can cause cancer cells to die.
  • What types of cancer is bortezomib being studied for in clinical trials? Clinical trials are exploring bortezomib's potential in treating various cancers, including multiple myeloma, non-Hodgkin's lymphoma, prostate cancer, ovarian cancer, and graft-versus-host disease after stem cell transplants.
  • How is bortezomib administered in clinical trials? In most trials, bortezomib is given as an injection into a vein (intravenously) or under the skin (subcutaneously). The dosing schedule varies but often involves treatments on specific days over a 21 or 28-day cycle.
  • What are researchers hoping to learn from these clinical trials? Researchers are studying bortezomib's effectiveness in treating different cancers, its safety profile, optimal dosing schedules, and how it performs when combined with other cancer treatments. They're also looking at its potential in overcoming drug resistance in some cancers.
  • Are there any known side effects of bortezomib? Common side effects observed in clinical trials include fatigue, nausea, diarrhea, decreased appetite, fever, and decreased blood cell counts. However, the full range of potential side effects is still being studied in these trials.

Ongoing Clinical Trials on Bortezomib

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on the Effects and Safety of Daratumumab, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Plasmablastic Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Bortezomib and Daratumumab for Patients with Primary Plasma Cell Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Greece

  • Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +3

  • Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +6

  • Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Greece

  • Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +5

Glossary

  • Proteasome inhibitor: A type of drug that blocks the action of proteasomes, which are cellular structures that break down proteins. By inhibiting proteasomes, these drugs can cause a buildup of proteins in cancer cells, leading to their death.
  • Graft-versus-host disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant, where the donor cells attack the recipient's body.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dose or require a dose reduction.
  • Allogeneic transplantation: A procedure where a person receives stem cells or bone marrow from a genetically similar, but not identical, donor.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland. Elevated levels may indicate prostate cancer or other prostate conditions.
  • Cytogenetic testing: The analysis of chromosomes to detect genetic abnormalities associated with certain cancers or other conditions.